



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/730,329	12/04/2000	Varghese John	00228-US-NEW3	8197
20350 7590 07/17/2007 TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			EXAMINER KAM, CHIH MIN	
			ART UNIT 1656	PAPER NUMBER
			MAIL DATE 07/17/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/730,329

Applicant(s)

JOHN ET AL.

Examiner

Chih-Min Kam

Art Unit

1656

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 April 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 6-10 and 22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 6, 8 and 9 is/are rejected.
- 7) ☒ Claim(s) 7, 10 and 22 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 28 August 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input checked="" type="checkbox"/> Other: <u>Sequence Error Report</u> |

DETAILED ACTION

Status of the Claims

1. Claims 6-10 and 22 are pending.

Applicant's amendment filed April 26, 2007 is acknowledged, and applicants' response has been fully considered. Claims 6, 7 and 22 have been amended. Therefore, claims 6-10 and 22 are examined.

Withdrawn Informalities

2. The previous objection to the specification regarding the description of drawings is withdrawn in view of applicants' amendment to the specification, and applicants' response at page 9 in the amendment filed April 26, 2007.

Withdrawn Claim Rejections - 35 USC § 112

3. The previous rejection of claim 22 under 35 U.S.C. 112, second paragraph, is withdrawn in view of applicant's amendment of the claim, and applicant's response at page 9 of the amendment filed April 26, 2007.

Sequence Listing

4. A paper copy and CRF of Sequence Listing filed April 26, 2007 is acknowledged. However, there are errors in the Sequence Listing (See attached Sequence Listing Error Report) Applicants must comply with the requirements of the sequence rules (37 CFR 1.821-1.825) and provide a copy of sequence listing and CRF containing all the sequences. Appropriate correction is required.

Claim Objection

Art Unit: 1656

5. Claim 6 is objected to because of the recitation of the term “V, A. E and F is/are replaced by a conservative substitution”, where a “comma”, not a “period” should be inserted between “A” and “E”.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 6, 8 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 6, 8 and 9 are indefinite because of the use of the term “wherein the phenyl group may optionally have.....”. The term cited renders the claim indefinite, it is not clear which phenyl group optionally has the substitution, and whether the phenyl group has the substitution or not. Claims 8 and 9 are included in this rejection for being dependent on a rejected claim and not correcting the deficiency of the claim from which they depend.

It is noted that in the previous amendment filed August 28, 2006, claim 6 does not recite the term “wherein the phenyl group may optionally have.....”. If this phrase is newly added to claim 6, it should be underlined to indicate this new addition.

Claim Objections

7. Claims 7, 10 and 22 are objected to because the claim is dependent from a rejected claim.

Conclusion

8. Claims 6, 8 and 9 are rejected; and claims 7, 10 and 22 are objected to.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Bragdon can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1656

Chih-Min Kam, Ph. D.
Primary Patent Examiner

A handwritten signature in black ink, appearing to read 'Chih-Min', followed by a long horizontal stroke.

CHIH-MIN KAM
PRIMARY EXAMINER

CMK

July 12, 2007

Sequence Error Report

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: markspencer

Timestamp: Fri May 11 14:31:34 EDT 2007

=====

Reviewer Comments:

<210> 73

<211> 9

<212> PRT

<213> Artificial

<220>

<223> P4-P4' staD-V peptide inhibitor

<220>

<221> MOD_RES

<222> (1)..(9)

<223> Xaa is statine moiety

* * * * *

Ser Glu Val Asn Xaa Val Ala Glu Phe

Xaa can only be a single amino acid residue.

Application No: 09730329

Version No: 3.0

Input Set:

Output Set:

Started: 2007-05-10 12:38:20.825
Finished: 2007-05-10 12:38:23.009
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 184 ms
Total Warnings: 67
Total Errors: 2
No. of SeqIDs Defined: 101
Actual SeqID Count: 101

ErrCode	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)
W 213	Artificial or Unknown found in <213> in SEQ ID (21)
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)

This error has occurred more than 20 times, will not be displayed

Input Set:

Output Set:

Started: 2007-05-10 12:38:20.825
Finished: 2007-05-10 12:38:23.009
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 184 ms
Total Warnings: 67
Total Errors: 2
No. of SeqIDs Defined: 101
Actual SeqID Count: 101

ErrCode	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (73)
E 341	'Xaa' position not defined SEQID (73) POS (5)

SEQUENCE LISTING

<110> John, Varghese
Sinha, Sukanto
Tung, Jay

<120> BETA-SECRETASE ENZYME COMPOSITIONS AND METHODS

<130> 015270-006460US

<140> 09730329

<141> 2000-12-04

<150> US 09/730,329

<151> 2000-12-02

<150> US 60/168,854

<151> 1999-12-02

<160> 101

<170> PatentIn version 3.3

<210> 1

<211> 1503

<212> DNA

<213> Homo sapiens

<400> 1

atggcccaag ccctgccctg gctcctgctg tggatggcg cgggagtgt gcctgccac	60
ggcaccagc acggcatccg gctgcccctg cgcagcggcc tggggggcgc ccccctggg	120
ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagctt	180
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc	240
gtgggcagcc cccgcagac gctcaacatc ctggtggata caggcagcag taactttgca	300
gtgggtgctg ccccccaccc ctctctgcat cgctactacc agaggcagct gtccagcaca	360
taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag	420
ctgggcaccg acctggtaag catcccccat ggccccaacg tcaactgtgc tgccaacatt	480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcacctg	540
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct	600
ctggtaaagc agaccacgt tcccaacctc ttctccctgc agctttgtgg tgctggcttc	660
cccctcaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggatc	720
gaccactcgc tgtacacagg cagtctctgg tatacaccca tccggcggga gtggtattat	780
gaggtgatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag	840

tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900
 gtgtttgaag ctgcagtcaa atccatcaag gcagcctect ccacggagaa gtccctgat 960
 gggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020
 ttcccagtca tctcactcta cctaattgggt gaggttacca accagtcctt ccgcatcacc 1080
 atccttcgc agcaatacct gcggccagtg gaagatgtgg ccacgtccca agacgactgt 1140
 tacaagtttg ccatctcaca gtcattccacg ggcactgtta tgggagctgt tatcatggag 1200
 ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1260
 catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
 gaagactgtg gctacaacat tccacagaca gatgagtcaa ccctcatgac catagcctat 1380
 gtcattggtg ccatctgcgc cctcttcatg ctgccactct gcctcatggt gtgtcagtgg 1440
 cgctgcctcc gctgcctgcg ccagcagcat gatgactttg ctgatgacat ctccctgctg 1500
 aag 1503

<210> 2
 <211> 501
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr

100

105

110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
 180 185 190

Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro
 195 200 205

Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
 210 215 220

Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
 225 230 235 240

Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
 245 250 255

Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270

Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
 275 280 285

Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
 290 295 300

Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
 305 310 315 320

Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
 325 330 335

Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
340 345 350

Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
355 360 365

Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
370 375 380

Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
385 390 395 400

Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
405 410 415

Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
420 425 430

Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
435 440 445

Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala
450 455 460

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp
465 470 475 480

Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp
485 490 495

Ile Ser Leu Leu Lys
500

<210> 3
<211> 24
<212> DNA
<213> Homo sapiens

<400> 3
gagagacgar garccwgagg agcc

<210> 4
<211> 24

<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 4
gagagacgar garccwgaag agcc 24

<210> 5
<211> 24
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 5
gagagacgar garccwgaag aacc 24

<210> 6
<211> 24
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 6
gagagacgar garccwgagg aacc 24

<210> 7
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 7
agagacgarg arccsgagga gcc 23

<210> 8
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 8
agagacgarg arccsgaaga gcc 23

<210> 9
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 9
agagacgarg arccsgaaga acc 23

<210> 10
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 10
agagacgarg arccsgagga acc 23

<210> 11
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 11
cgtcacagrt trtcaaccat ctc 23

<210> 12
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 12
cgtcacagrt trtctaccat ctc 23

<210> 13
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 13
cgtcacagrt trtccacat ctc

23

<210> 14
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 14
cgtcacagrt trtcgacat ctc

23

<210> 15
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 15
cgtcacagrt trtcaacat ttc

23

<210> 16
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 16
cgtcacagrt trtctacat ttc

23

<210> 17
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 17
cgtcacagrt trtccacat ttc

23

<210> 18
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 18
cgtcacagrt trtcgaccat ttc 23

<210> 19
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 19
gaggggcagc tttgtggaga 20

<210> 20
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 20
cagcataggc cagccccagg atgcct 26

<210> 21
<211> 24
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 21
gtgatggcag caatgttggc acgc 24

<210> 22
<211> 17
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, or t

<400> 22
gaygargagc cngagga

17

<210> 23
<211> 17
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, or t

<400> 23
gaygargagc cngaaga

17

<210> 24
<211> 17
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, or t

<400> 24
gaygargaac cngagga

17

<210> 25
<211> 17
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(17)
<223> N = A, C, G, or T

<400> 25
gaygargaac cngaaga

17

<210> 26
<211> 15
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(15)
<223> N = A, C, G, or T

<400> 26
rttrtcnacc atttc 15

<210> 27
<211> 15
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(15)
<223> N = A, C, G, or T

<400> 27
rttrtcnacc atctc 15

<210> 28
<211> 17
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(17)
<223> N = A, C, G, or T

<400> 28
tcnaccatyt cnacaaa 17

<210> 29
<211> 17

<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(17)
<223> N = A, C, G, or T

<400> 29
tcnaccatyt cnacgaa

17

<210> 30
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 30
atattctaga gaygargagc cagaaga

27

<210> 31
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 31
atattctaga gaygargagc cggaaga

27

<210> 32
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 32
atattctaga gaygargagc ccgaaga

27

<210> 33
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 33
atattctaga gaygargagc ctgaaga

27

<210> 34
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(30)
<223> N=A, C, G, or T

<400> 34
acacgaattc ttrtcnacca tytcaacaaa

30

<210> 35
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(30)
<223> N = A, C, G, or T

<400> 35
acacgaattc ttrtcnacca tytcgacaaa

30

<210> 36
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(30)
<223> N = A, C, G, or T

<400> 36
acacgaattc ttrtcnacca tytccacaaa 30

<210> 37
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<220>
<221> misc_feature
<222> (1)..(30)
<223> N = A, C, G, or T

<400> 37
acacgaattc ttrtcnacca tytctacaaa 30

<210> 38
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 38
aagagcccgg ccggaggggc a 21

<210> 39
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 39
aaagctgccc ctccggccgg g 21

<210> 40
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 40
agctcgttta gtgaaccgtc agatcg 26

<210> 41
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Degenerate oligonucleotide primer

<400> 41
acctacaggt ggggtctttc attccc 26

<210> 42
<211> 2348
<212> DNA
<213> Homo sapiens

<400> 42
ccatgccggc ccctcacagc cccgccggga gcccagagccc gctgcccagg ctggccgccc 60
csgtgccgat gtagcgggct ccggatccca gcctctcccc tgetcccggtg ctctgcggat 120
ctccccgtac cgctctccac agcccggacc cgggggctgg cccagggccc tgcaggccct 180
ggcgtcctga tgccccaag ctccctctcc tgagaagcca ccagcaccac ccagacttgg 240
gggcaggcgc cagggacgga cgtgggccag tgcagagcca gagggcccga aggccggggc 300
ccaccatggc ccaagccctg ccctggctcc tgctgtggat gggcgcgga gtgctgcctg 360
cccacggcac ccagcacggc atccggctgc ccctgcgcag cggcctgggg ggcgcccccc 420
tggggctgctg gctgccccgg gagaccgacg aagagcccga ggagcccggc cggaggggca 480
gctttgtgga gatggtggac aacctgaggg gcaagtccgg gcagggtac tacgtggaga 540
tgaccgtggg cagccccccg cagacgtca acatcctggt ggatacaggc agcagtaact 600
ttgcagtggg tgctgcccc cacccttcc tgcacgcta ctaccagagg cagctgtcca 660
gcacataccg ggacctccgg aagggtgtgt atgtgcccta caccagggc aagtgggaag 720
gggagctggg caccgacctg gtaagcatcc cccatggccc caacgtcact gtgcgtgcca 780
acattgctgc catcactgaa tcagacaagt tcttcatcaa cggctccaac tgggaaggca 840
tcctggggct ggcctatgct gagattgcca ggctgacga ctccctggag cctttctttg 900
actctctggt aaagcagacc cacgttccca acctcttctc cctgcagctt tgtggtgctg 960
gcttccccct caaccagtct gaagtgtgg cctctgtcgg agggagcatg atcattggag 1020
gtatcgacca ctgctgtac acaggcagtc tctggtatac acccatccgg cgggagtggg 1080
attatgaggt gatcattgtg cgggtggaga tcaatggaca ggatctgaaa atggactgca 1140

aggagtacaa ctatgacaag agcattgtgg acagtggcac caccaacctt cgtttgccca	1200
agaaagtgtt tgaagctgca gtcaaacca tcaaggcagc ctctccacg gagaagttcc	1260
ctgatgggtt ctggctagga gagcagctgg tgtgctggca agcaggcacc accccttgga	1320
acattttccc agtcattctca ctctacctaa tgggtgaggt taccaaccag tccttcgcga	1380
tcaccatcct tccgcagcaa tacctgcggc cagtgaaga tgtggccacg tccaagacg	1440
actgttacia gtttgccatc tcacagtcac ccacgggcac tggtatggga gctgttatca	1500
tggagggtt ctacgttgc tttgatcggg ccgaaaacg aattggcttt gctgtcagcg	1560
cttgccatgt gcacgatgag ttcaggacgg cagcgtgga aggcctttt gtcaccttg	1620
acatgaaga ctgtggctac aacattccac agacagatga gtcaaccctc atgaccatag	1680
cctatgtcat ggctgccatc tgcgccctct tcattgtgcc actctgcctc atggtgtgtc	1740
agtggcgctg cctccgctgc ctgcgccagc agcatgatga ctttgctgat gacatctccc	1800
tgtgaagtg aggaggecca tgggcagaag atagagattc cctggacca cacctccgtg	1860
gttcactttg gtcacaagta ggagacacag atggcacctg tggccagagc acctcaggac	1920
cctccccacc caccaaatgc ctctgccttg atggagaagg aaaaggctgg caagggtgggt	1